Business Wire

OR-RADISYS/TALLENCE

16.12.2020 14:02:11 CET | Business Wire | Press release

Share
Tallence Selects Radisys’ Engage Platform as Foundation for New Cloud Messaging Solution

Radisys® Corporation , a global leader of open telecom solutions, today announced that Tallence AG , a digital transformation technology and management consultancy, has selected Radisys’ Engage Media Server as the foundation for a new voice messaging system for a Tier 1 European operator. Tallence will leverage the extensive capabilities of the Engage Media Server, a foundational element of the Radisys Engage communications services enablement platform, to create enhanced digital customer experiences with high quality interactions and augment content to create greater customer satisfaction and increase customer loyalty.

Highlights

  • Digital communications solutions continue to become more integrated into both mobile and web paths of the customer journey. The COVID-19 pandemic is accelerating the shift in customer experience to online solutions. Application developers and Communication Service Providers (CSPs) must be able to quickly bring online new, scalable and elastic services that can be adapted to changing market conditions. With the right platform, they can meet the combined challenges of rapid increases and fluctuations in customer access traffic and increasingly remote, distributed workforces, all while enabling a top quality seamless experience.
  • Traditionally, only large enterprises had the infrastructure and budgets to deliver compelling digital experiences that seamlessly tie voice and video interaction with content and business processes. By migrating these services to the cloud on the foundation of Radisys’ Engage Media Server, Tallence is providing services that enable businesses of all sizes to reach their consumers at lower cost, with greater flexibility, and optimal use of resources.
  • Radisys’ Engage Media Server delivers a rich set of media capabilities for developers and CSPs to create enhanced and engaging digital customer experiences. It provides the foundation for high-value voice and video features to enrich digital experience applications, and it enables CSPs to leverage the cloud for low cost and increased efficiency with industry-leading capacities for best total cost of ownership. The cloud-based Engage Media Server delivers:
    • On demand scalability which reduces costs for broad market reach for digital experience applications and services at attractive price points.
    • Optimal user experiences that tie to brand and customer satisfaction by using high quality voice and video, including real-time processing for 4G and 5G, PSTN, and web or mobile app modalities that can adapt to various bandwidth and network conditions and ensure CSPs can meet even the most rigorous availability and quality service level agreements with their customers.
    • Powerful tools for application developers to quickly bring to market applications and services and on-demand adaptation for new campaigns through industry-leading analytics.

“Radisys’ Engage Media Server delivers the scalability and capabilities required for exceptional digital experience-related services for our new cloud-based voice messaging solution deployed for our tier-one customer,” said Christian Schöntag, Head of Consulting, Tallence AG. “Furthermore, Radisys’ extensive experience in cloud-based media processing is critical for enabling us to ensure reliability and scalability for our customers as they accelerate their move to the cloud.”

“Tallence AG has an impressive reputation in delivering innovative customer experiences that can provide compelling ROIs for their customers and sticky, loyalty building experiences for their end users,” said Al Balasco, Radisys’ Head of Media, Core and Applications Business. “Our Engage platform is deployed by over 150 operators and currently serves 2 billion users worldwide. Tallence’s cloud-based application builds on this mobile network-optimized platform to deliver services for a new age and represents the value of our media server to leading solution providers in enabling digital consumer experiences and e-commerce services.”

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .

About Tallence

Tallence AG is a technology and management consultancy for digital transformation. We support our customers in using digitalization to their advantage and creating competitive advantages. We advise, develop and manage with a hands-on and result-oriented approach. Whether international technology group, traditional medium-sized enterprises or public sector: The benefit for the end customer is always the guiding principle and driving force behind Tallence. We ensure this through genuine expert performance and the highest level of commitment. Our clients come from diverse industries including telecommunications, information, media and energy. At Tallence AG more than 150 IT developers, machine learning specialists and management consultants based in our German office locations in Hamburg, Frankfurt, Marburg, Görlitz and Karlsruhe are working on future-oriented topics of the Digital Economy. Read more on: www.tallence.com .

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye